Ekso Bionics® Launches EksoPulse Cloud-Based Analytics
RICHMOND, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the worldwide launch of EksoPulse, an advanced cloud-based information technology platform that enhances the clinician, institutional and patient experience with the Ekso GT™ robotic exoskeleton. EksoPulse operates in conjunction with technologies from leading global companies to support the new system with EksoPulse Analytics.
The new EksoPulse platform technology uniquely allows physical therapists (PTs) to personalize patient care with the Ekso GT. The technology allows PTs to not only capture patient progress during sessions, but to store the therapeutic data in a cloud-based system, to synchronize that data with cellular technology in order to track changes in patient performance and to then make real-time adjustments to care plans. Key features of EksoPulse include enhanced data analytics, cellular data transmission and cloud-based data storage capabilities, which allow a physician or PT to access rehabilitation measures via a secure web-based portal.
“The proprietary EksoPulse technology allows our customers to offer personalized care and rehabilitation for their patients by analyzing each individual’s utilization on the Ekso GT,” commented Thomas Looby, president and chief executive officer of Ekso Bionics. “We are committed to continuous innovation and enhancements in our technology and to positively impacting the well-being of patients.”
EksoPulse is commercially available to rehabilitation centers around the world that are using the newest generation Ekso GT with SmartAssist, a comprehensive gait therapy software. The data from EksoPulse can be reviewed on the portal by users through a PC or Mac and clinicians can access patient information at any time to make informed decisions, which could have a significantly positive impact on patient care and recovery.
"Using EksoPulse lets me objectively track a patient's progress. It saves me time because I know each session's data is accurately documented and the filtering tools make it quick and easy to find an individual's records," commented Antoinette Domingo, PT, PhD, Assistant Professor in the Doctor of Physical Therapy Program at San Diego State University.
Ekso Bionics will have presentations and demonstrations and will also be showcasing the Ekso GT with EksoPulse at the following conferences:
Association of Academic Physiatrists (AAP) 2017 Meeting
- February 7-11, 2017 – Las Vegas, Nevada
- Live Demonstrations: Booth #432
- Lunch Symposium: February 9 – 12:30 - 1:30 pm; Exhibit Hall / Dining Area
American Physical Therapy Association Combined Sections Meeting (CSM) 2017:
- February 15-18, 2017 - San Antonio, Texas
- Hands-on Workshop for SmartAssist: Booth #342
- Afterhours Event: February 16 – 5:00 - 6:30 pm; Booth #342
To learn more about EksoPulse or Ekso GT, visit www.eksobionics.com
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 130 rehabilitation institutions around the world.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the period and year ended December 31, 2016, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Annual Report on Form 10-K that are required to be included therein, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 email@example.com Investor Contact: Debbie Kaster 415-937-5403 firstname.lastname@example.org
Released February 9, 2017